initial therapeutics, inc.
285 east grand avenue
south san francisco, ca 94080
We start with targets known to play key roles in disease, and design molecules to enter the ribosome – the machine of the cell itself – to selectively stall the formation of these pathogenic proteins.
ATP IS DEVELOPING THE NEXT GENERATION OF TRANSFORMATIVE LIFE SCIENCES COMPANIES.